Mastek Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/d2ivfvwcy7mdib8nhszkkxpo.pdf

Key Takeaways


Demand Environment & Revenue Performance

Umang Nahata: "We believe it will be a growth year next year based on the fundamentals that have improved in this fiscal."

AI Strategy & Deal Evolution

Umang Nahata: "When it becomes enterprise scale, and it will become enterprise scale because it is not just about 1 or 2 workflows. It has to change the entire landscape of business. That's where sizable revenue and business impact will happen, which will clearly overthrow whatever we have been doing so far and significantly increase that. But like I said, I can only tell you lead indicators, exact timing is unknown."

Margins & Efficiency

Umang Nahata: "The T&M model will give way to more outcome-focused model."

Geographic & Vertical Reset


Capital Allocation & Corporate Actions


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthFY27 will be a positive growth year, faster than FY26, based on improved fundamentals and order backlogFY27
EBITDA marginMaintain at 16% to 16.1%, balancing efficiency gains against pricing pressure and AI investmentsFY27
North America turnaroundOrder book growth to continue sequentially, resulting in positive revenue growthFY27
Healthcare recoveryGrowth expected to return soon; timing gap between projects going live and new ones startingNear term, undated
FCA deal ramp-upFully ramped up with resources deployedEnd of Q1 FY27
ATLAS & Biometric ramp-upsNew SOWs being negotiated; ramp-ups expectedBetween Q1 and Q2 FY27
AMEA turnaroundTurning towards growth, conditional on geopolitical uncertainties being eliminatedFY27, conditional
Tax rateAverage effective rate of 24.5% to 24.7%Ongoing
Business model shiftFixed-bid percentages to grow further from ~40% company-wide and >50-55% in North AmericaUndated
Headcount efficiencyEmployee growth rate will be slower than revenue growth; revenue per resource to move positivelyUndated

Key Metrics

MetricQ4 FY26
Revenue$103.5 million, +1.4% QoQ; +0.3% QoQ in constant currency
Revenue (INR)₹938 crores, +3.6% QoQ and +3.6% YoY
Operating EBITDA margin16.1%, salary increase impact of 1.1% offset by forex tailwind of 0.8% and cost efficiencies
PAT₹106 crores, 11% of revenue; -0.7% QoQ due to Labor Code true-up impact
12-month order backlog$300.4 million, +1.5% QoQ and +13.5% YoY in USD; +24.4% YoY in INR
Order backlog growth (INR)+7.2% QoQ; +1.6% QoQ in USD terms
Full-year FY26 revenue$421.2 million, +3.1% YoY; ₹3,699 crores, +7% YoY
Full-year FY26 EBITDA margin15.8%, flat YoY
Full-year FY26 PAT₹404 crores, +7.5% YoY; 10.7% of total income, flat YoY
Basic EPS (FY26)₹130.45, +7.1% YoY
Diluted EPS (FY26)₹129.5, +7.3% YoY
Operating cash flow (FY26)₹542 crores, +35% YoY
Cash and cash equivalents₹938 crores as of March 2026, +51% YoY
DSO73 days, lowest in last 12 quarters; Q4 collections of $125 million
Total headcount4,730, net addition of 54 during the quarter
Utilization rate80%, +3.3 ppt QoQ and +1.7 ppt from Q2
Revenue per resource growth (FY26)+12% for the full year
New customers added12 during the quarter
Net new AI-focused customer programs27 programs added in the quarter
U.K. & Europe revenue growth (FY26)~11% in pound terms; 21.8% in INR terms
U.K. healthcare revenue growth (FY26)~24% in dollar terms; 90-plus percent in INR terms
U.K. EBITDA margin~20%
Fixed-bid business share~40% at company level; >50–55% in North America
Labor Code exceptional impact (Q4)₹23.7 crores incremental impact, including gratuity of ₹16 crores and leave encashment of ₹7.7 crores
Dividend₹16 per share final dividend, on top of ₹8 interim; total 480% of face value